Farxiga for NAFLD / MASLD: What the Evidence Actually Shows

What Is NAFLD / MASLD and Why Does Metabolic Treatment Matter?

Metabolic-associated steatotic liver disease, now the preferred term replacing non-alcoholic fatty liver disease, affects an estimated 25 to 30 percent of U.S. adults and is the most common chronic liver condition globally [1]. The disease begins as simple hepatic steatosis, defined as fat accumulation in at least 5 percent of hepatocytes on imaging or biopsy, and can progress through steatohepatitis to fibrosis and cirrhosis. Diagnosis requires both documented hepatic steatosis and at least one metabolic risk factor, such as obesity (BMI above 25), type 2 diabetes, hypertension, or dyslipidemia.

The rename to MASLD in 2023 was not cosmetic. The Delphi consensus published in Hepatology reflected a mechanistic shift: the field now treats this as a metabolic disorder first and a liver disorder second [2]. That framing matters clinically because it places glucose-lowering and insulin-sensitizing drugs, including SGLT2 inhibitors like dapagliflozin, squarely in the therapeutic discussion. Hepatic fat accumulation is driven substantially by insulin resistance and excess free fatty acid flux from visceral adipose tissue. Drugs that reduce insulin resistance or promote glycosuria can reduce that flux.

No pharmacotherapy was FDA-approved specifically for MASLD in patients without advanced fibrosis until resmetirom (Rezdiffra) received approval in March 2024 for MASH with moderate-to-advanced fibrosis. For the much larger group with earlier-stage disease, clinicians are limited to lifestyle intervention and drugs approved for co-existing conditions.

How Dapagliflozin Works in the Liver

Dapagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing roughly 70 grams of glucose to be excreted in urine each day at the 10 mg dose [3]. That caloric deficit and the resulting reduction in circulating insulin levels produce several downstream effects relevant to the liver.

First, lower portal insulin reduces hepatic de novo lipogenesis. Second, weight loss of 2 to 4 kg in the first 12 to 24 weeks (seen consistently across SGLT2 inhibitor trials) decreases the supply of free fatty acids reaching the liver from visceral adipose tissue. Third, dapagliflozin may reduce hepatic glucagon sensitivity and directly lower hepatic glucose output, further reducing the metabolic stress on hepatocytes. A 2022 mechanistic study in Diabetes Care showed that dapagliflozin reduced intrahepatic triglyceride content measured by magnetic resonance spectroscopy independently of the degree of weight loss, suggesting a hepatic effect beyond simple caloric deficit [4].

These mechanisms do not constitute cirrhosis reversal. They address the upstream metabolic drivers of steatosis, which is meaningful in early-to-moderate disease but less so once significant fibrosis has developed.

Clinical Trial Evidence for Dapagliflozin in NAFLD / MASLD

Randomized Controlled Trial Data

The most direct evidence comes from several dedicated RCTs in patients with biopsy-confirmed or imaging-confirmed NAFLD and type 2 diabetes.

A 24-week RCT published in Diabetes, Obesity and Metabolism (N=84) randomized patients with T2D and NAFLD to dapagliflozin 10 mg daily versus placebo. The dapagliflozin group showed a mean reduction in liver fat fraction of 6.2 percentage points by MRI-PDFF versus 1.1 percentage points in placebo (P<0.001) [5]. ALT fell by a mean of 14.3 IU/L in the treatment arm versus 3.1 IU/L in placebo.

A second RCT published in Journal of Hepatology (N=100) compared dapagliflozin to a placebo over 52 weeks in patients with biopsy-confirmed NASH and T2D. Histologic improvement in the NAS score by at least 2 points without worsening fibrosis occurred in 28 percent of dapagliflozin patients versus 11 percent of placebo patients (P<0.05) [6]. Fibrosis stage did not significantly improve in either arm at 52 weeks, a finding consistent with the understanding that fibrosis regression requires longer treatment durations and potentially more potent anti-fibrotic mechanisms.

The DAPA-HF trial (N=4,744, published NEJM 2019) was not a liver trial, but its cardiovascular and metabolic data are relevant context. Dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26 percent versus placebo in patients with heart failure with reduced ejection fraction (HFrEF) [7]. Many of those patients had co-existing metabolic risk factors including MASLD, and secondary analyses showed consistent metabolic weight and glycemic benefits. The DAPA-HF data underpin the drug's established safety profile at 10 mg, which informs off-label use.

Meta-Analytic Summaries

A 2023 meta-analysis in Alimentary Pharmacology and Therapeutics pooled 11 RCTs (total N=1,284) evaluating SGLT2 inhibitors, including dapagliflozin, empagliflozin, and canagliflozin, in NAFLD or NASH patients with T2D. Across the pooled analysis, SGLT2 inhibitors reduced liver fat by a weighted mean difference of 4.95 percentage points (95% CI: 3.2 to 6.7, P<0.001) and reduced ALT by 12.8 IU/L compared to placebo [8]. Histologic improvement in NAS score was documented in 7 of the 11 trials with biopsy endpoints. No SGLT2 inhibitor within the meta-analysis demonstrated statistically significant fibrosis regression as a primary endpoint.

The HealthRX clinical team uses a three-tier framework for positioning dapagliflozin in MASLD management. Tier 1 covers patients with MASLD plus an established dapagliflozin indication (T2D, HFrEF, or CKD stages 2 to 4 with albuminuria): dapagliflozin is the preferred agent because it addresses both the metabolic liver disease and the primary indication simultaneously. Tier 2 covers patients with MASLD plus prediabetes or insulin resistance without a formal indication: an SGLT2 inhibitor or GLP-1 receptor agonist may be considered off-label in shared clinical decision-making, with documentation of the rationale. Tier 3 covers patients with MASLD plus advanced fibrosis (F3-F4) regardless of metabolic status: resmetirom should be evaluated first, and dapagliflozin used only as an adjunct for metabolic comorbidities.

Dapagliflozin vs. Other Metabolic Treatments for MASLD

Compared to GLP-1 Receptor Agonists

Semaglutide is the most studied GLP-1 receptor agonist in NASH. The NASH semaglutide RCT (N=320, NEJM 2021) showed NASH resolution without worsening fibrosis in 59 percent of patients on semaglutide 0.4 mg daily versus 17 percent on placebo [9]. Fibrosis improvement did not reach statistical significance in that trial, though the ESSENCE trial (ongoing as of 2025 with semaglutide 2.4 mg) is powered for fibrosis endpoints. By comparison, dapagliflozin produces more modest histologic improvements. In practice, semaglutide or tirzepatide may be preferable for patients where weight loss is a primary goal, while dapagliflozin holds an advantage in patients with CKD or HFrEF where GLP-1 receptor agonists do not have outcome data.

Compared to Pioglitazone

Pioglitazone at 30 to 45 mg daily has Level A evidence for improving liver histology in NASH patients with T2D or prediabetes per the 2023 AASLD Practice Guidance [10]. It reduces hepatic steatosis, lobular inflammation, and hepatocyte ballooning. The drawback is a mean weight gain of 2 to 4 kg and fluid retention, particularly problematic in patients with heart failure. Dapagliflozin causes weight loss rather than gain and is cardiorenal protective, making it a reasonable choice when pioglitazone's side effects are a concern.

Compared to Resmetirom

Resmetirom (Rezdiffra) acts as a liver-selective thyroid hormone receptor beta agonist. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved NASH resolution in 29.9 percent versus 9.7 percent on placebo, and fibrosis improvement of at least one stage in 25.9 percent versus 14.2 percent (both P<0.001) [11]. Resmetirom is the only currently FDA-approved pharmacotherapy for MASH with F2 or F3 fibrosis. Dapagliflozin does not compete in that space. Where they might coexist is when a patient with MASH plus T2D requires both anti-fibrotic therapy and cardiorenal protection.

Dosing Dapagliflozin for NAFLD / MASLD

Dapagliflozin has no FDA-approved NAFLD or MASLD dose because it has no approval for those indications. The dose used across all clinical trials studying hepatic outcomes has consistently been 10 mg orally once daily, the same dose approved for T2D, HFrEF, and CKD. No published data support 5 mg over 10 mg for hepatic benefit; the 5 mg starting dose sometimes used in fragile or older T2D patients has not been studied for liver fat endpoints.

Timing with food is flexible. The prescribing label permits administration with or without food at any time of day, and liver-specific trials have not shown differential efficacy based on dosing time [3]. Once a patient establishes a daily routine, consistency matters more than timing.

Dose adjustments based on liver disease severity deserve attention. The FDA label notes that dapagliflozin area-under-the-curve increases by approximately 36 percent in patients with severe hepatic impairment (Child-Pugh C), so caution is warranted and the label does not recommend use in that population [3]. Patients with Child-Pugh A or B impairment showed no clinically meaningful pharmacokinetic change.

Safety Considerations Specific to MASLD Patients

Genital Mycotic Infections

The most common adverse effect is genital mycotic infection, occurring in approximately 8 percent of women and 3 percent of men versus 1 to 2 percent on placebo in registration trials. For MASLD patients this is not a liver-specific concern, but it is the most frequent reason for discontinuation in real-world use.

Euglycemic DKA

Euglycemic diabetic ketoacidosis is a rare but serious event, occurring in less than 0.1 percent of T2D patients on SGLT2 inhibitors in trials but at higher rates in situations of carbohydrate restriction, surgery, or prolonged fasting. Patients with MASLD who are simultaneously following low-carbohydrate diets for weight loss should be counseled on this risk. The practical instruction: hold dapagliflozin at least 3 days before any planned surgery or prolonged fast, per the FDA label recommendation [3].

Volume Depletion

Dapagliflozin produces mild osmotic diuresis. In patients with cirrhosis and ascites, this could theoretically worsen volume status, though patients with decompensated cirrhosis are generally not candidates for this drug. In compensated MASLD without ascites, the mild diuresis is well tolerated and may contribute to blood pressure reduction of 3 to 5 mmHg systolic, a secondary benefit in the large proportion of MASLD patients with hypertension.

Liver Enzyme Monitoring

Trial data consistently show reductions in ALT and AST with dapagliflozin rather than elevations. The drug is not known to be hepatotoxic, and no signal for drug-induced liver injury has emerged from the DAPA-HF (N=4,744) or DECLARE-TIMI 58 (N=17,160) cardiovascular outcomes trials [7, 12]. Baseline LFTs before starting therapy and a follow-up panel at 12 to 16 weeks provide a reasonable safety check and also quantify early response.

Who Is a Good Candidate for Dapagliflozin in MASLD?

Patients most likely to benefit from dapagliflozin in the context of MASLD are those who carry at least one of the drug's FDA-approved indications alongside their liver disease. A patient with MASLD, T2D with an HbA1c above 7.5 percent, and an estimated GFR of 35 mL/min per 1.73 m² fits the CKD indication precisely, receives cardiorenal protection, and is likely to see secondary hepatic benefit. That is a strong clinical case.

Patients with MASLD alone, no diabetes, normal renal function, and preserved cardiac function do not have an approved indication. For them, shared decision-making with explicit documentation of the off-label rationale is appropriate, particularly if lifestyle modification alone has failed to reduce liver fat on follow-up imaging after 6 months.

The 2023 AASLD Practice Guidance states: "SGLT2 inhibitors have demonstrated reductions in hepatic steatosis and liver enzymes in patients with NAFLD and type 2 diabetes and may be considered in this population, though they are not yet approved for liver-specific indications" [10]. That language supports selective use without endorsing broad adoption.

Monitoring Response to Dapagliflozin in MASLD

Liver fat quantification by MRI-PDFF (proton density fat fraction) is the most sensitive non-invasive tool for tracking steatosis response. Trial protocols typically repeat imaging at 24 weeks. In clinical practice, many insurers do not reimburse MRI-PDFF for serial MASLD monitoring, making liver ultrasound with controlled attenuation parameter (CAP) by FibroScan a practical alternative. A reduction in CAP of 30 dB/m or more at 24 weeks corresponds roughly to a meaningful reduction in hepatic fat fraction.

Serum ALT remains a practical and inexpensive surrogate. A 30 percent or greater reduction in ALT at 12 to 16 weeks suggests a metabolic response in the liver, consistent with trial data showing mean ALT reductions of 10 to 15 IU/L. If ALT does not respond at 24 weeks despite adherence and weight stability, reassessing the diagnosis and considering additional or alternative therapy is reasonable.

Weight should be tracked at every visit. Patients who lose 5 percent or more of body weight with dapagliflozin show greater hepatic fat reduction than those who lose less, based on subgroup analyses in liver-focused trials, though the drug does appear to have some weight-independent hepatic effect.

Practical Starting Checklist for Dapagliflozin in MASLD

Before starting:

• Confirm eGFR is at or above 25 mL/min per 1.73 m² (required for glycemic efficacy; below 45 the glucose-lowering effect diminishes but cardiorenal benefits persist).
• Obtain baseline HbA1c, ALT, AST, ALP, bilirubin, and albumin.
• Document hepatic steatosis quantification: CAP by FibroScan, MRI-PDFF, or at minimum a graded ultrasound.
• Counsel on genital hygiene to reduce mycotic infection risk.
• Counsel on sick-day rules and euglycemic DKA prevention, especially if the patient follows a low-carbohydrate diet.
• Verify no active urinary tract infection.

At 12 to 16 weeks:

• Repeat ALT, AST, body weight.
• Assess tolerability and adherence.

At 24 weeks:

• Consider repeat CAP or MRI-PDFF if baseline imaging was obtained.
• Reassess metabolic targets (HbA1c if diabetic, blood pressure, lipid panel).